Ren et al. and Cao et al. developed BCMA-specific CAR-NK cells targeting MM, enhancing cytotoxicity and survival in mouse models [240, 241], with ongoing clinical trials (NCT03940833 and NCT05182073) exploring their therapeutic potential. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.